sirtris pharmaceuticals stock price

News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services Too bad, since exactly happened what I had suggested: a big player is now trying to buy the company. Sirtris founder and CEO Christoph Westphal will remain head of the unit once the cash sale of about $22.50 per share closes later this year. weekly.TradingCharts.com offers over 30 thousand free stock price charts and stock market quotes. Its SIRT-501, which is in early-stage development, is an enhanced formulation of resveratrol (the healthful agent found in red wine) that targets one of those enzymes, SIRT1. The startup’s activity is discovering and developing proprietary, orally available, small molecule drugs with the potential to treat metabolic diseases such as Type 2 Diabetes and such of aging by modulating sirtuins, a recently discovered class of enzymes. GlaxoSmithKline is paying big in an effort to find cures for diseases of aging. Type 2 Diabetes (T2D) has reached epidemic proportions in the United States. The $22.50 per Sirtris share that GSK paid as part of the deal represented a nearly 85 percent premium to Sirtris’ stock price at the time the deal was announced. Their stock opened with $10.00 in its May 23, 2007 IPO. Sirtris Pharmaceuticals Inc. Another hot stock is Sirtris Pharmaceuticals. Developer of proprietary, orally administrable, small molecule biopharmaceutical drugs intended to cure type 2 diabetes, cancer, and other diseases. Under the agreement, a subsidiary of GSK will commence a cash tender offer to purchase all of the outstanding shares of Sirtris, at USD22.50 (or approx. Big pharma companies, pained by generic competition, have turned to licensing deals and acquisitions to bolster their pipelines. GBP11.33) per share followed by a second step merger in which any untendered Sirtris shares would be acquired at the same price per share. They are buying Sirtris Pharmaceuticals for $720M in cash, or $22.50/share. Sirtris Pharmaceuticals, Inc. SEC Form 4 Filed December 4, 2007: Statement of changes in beneficial ... Last Updated December 17, 2020 at 7:56 AM EST Back to Sirtris Pharmaceuticals, Inc. Sirtris shares closed down 4% Tuesday prior to the news, at $12.23. © 2021 TheStreet, Inc. All rights reserved. //-->. Sirtris Pharmaceuticals Files for $60 Million IPO Published: Mar 01, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sirtris Pharmaceuticals Inc. today announced that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. M&A. Markets Data Center: Biggest Price Gainers. Markets Data Center: Biggest Price Gainers. Latest Deal Amount. READ MORE Prior to co-founding our company, Dr. Milne worked as head of discovery biology at Sirtris Pharmaceuticals, a biotechnology company, from 2004 to 2008, when it was acquired by GlaxoSmithKline. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. The company also has discovered new chemical entities that are significantly more potent activators of SIRT1 and should enter the clinic this year, according to some analysts. The acquisition has been approved by the boards of both companies, and is expected to close in the second quarter. if ((navigator.appVersion.indexOf("MSIE") > 0) && (parseInt(navigator.appVersion) >= 4)) { Company profile page for Sirtris Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information A high-level overview of Sirtris Pharmaceuticals (SIRT) stock. document.write("
Click here to add this page to your favorites"); The news comes a day before Glaxo's quarterly earnings release. Sirtris Pharmaceuticals Inc. filed with regulators on Thursday to raise up to $60 million in an initial public offering of common stock. And Sirtris says it is close to launching clinical trials for experimental drugs that could prove to be up to 1,000 times more potent. Sirtris Pharmaceuticals (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. Big pharma companies, pained by generic competition, have turned to licensing deals and acquisitions to bolster their pipelines. Sirtris is the most high-profile shop working on sirtuins and resveratrol-like pharmacology, which subject has received a massive amount of … This stock price chart for SIRTRIS PHARMA INC., symbol SIRT, Nasdaq Stock Exchange is updated GlaxoSmithKline today announced that it is going to acquire Sirtris (NASDAQ:SIRT) for $720 million through a cash tender offer of $22.50 per share. } GlaxoSmithKline (GSK) - Get Report announced Tuesday after the market closed that it is buying Sirtris Pharmaceuticals (SIRT) for $720 million, or $22.50 a share. Sirtris Pharmaceuticals is registered under the ticker NASDAQ:SIRT . [6] Studies published in 2009 and early 2010 by scientists from Amgen and Pfizer cast doubt on whether SIRT1 was directly activated by resveratrol and showed that the apparent activity was actually due to a fluorescent reagent used in the experiments. Description. News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services Sirtris Pharmaceuticals (NASDAQ:SIRT) ... as seen by today's 15% drop in the stock price, the stock still looks a little overpriced for a company with one drug in … Sirtris Pharmaceuticals Presents Results of Studies of SIRT1 Activators at 6th Annual Metabolic Diseases Drug Discovery and Development World Summit, July 17, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 17, 2007 - Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat … When I pointed at Sirtris Pharmaceuticals in February I was considering to invest in that stock but had no money left. Post-acquisition, Sirtris will become part of Glaxo's drug discovery organization, while continuing to operate from laboratories in Cambridge, Mass., as an autonomous drug discovery unit. And Sirtris/GSK faces long years of rigorous research before this nook of the anti-aging field yields a marketed drug. via: Sirtris Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more. Stock Symbol NASDAQ:SIRT ; Money Raised at IPO $60M; IPO Share Price $10.00; IPO Date May 23, 2007; Delisted Date Mar 13, 2013 Sirtris Pharmaceuticals ' first drug is a treatment for diabetes. Action Alerts PLUS is a registered trademark of TheStreet, Inc. The planned purchase of the biopharma comes at a $10-a-share premium over Tuesday's closing price. Sirtris Pharmaceuticals™ (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. [Updated 2:25 pm ET, 3/13/13] GlaxoSmithKline is closing down Cambridge, MA-based Sirtris Pharmaceuticals, almost five years after it paid $720 million to … Biopharmaceutical company Sirtris Pharmaceuticals Inc. said it would sell 5 million shares in its initial public offering at $9 to $11 apiece. GSK paid $22.50/share, when Sirtris's stock was trading at $12/share, down 45% from its highest price of the previous year. Sirtris PharmaceuticalsGeneral Information. TradingCharts.com offers over 30 thousand free stock price charts and stock market quotes. Find the latest Genocea Biosciences, Inc. (GNCA) stock quote, history, news and other vital information to help you with your stock trading and investing. Sirtris Pharmaceuticals has established a drug discovery capability to exploit sirtuin modulation for the treatment of human disease, an approach that has the potential to generate multiple clinically and commercially important products. The stock market hasn't been kind to Sirtris, which was trading at $12, down 45% from its 52-week high. This stock price chart for SIRTRIS PHARMA INC., symbol SIRT, Nasdaq Stock Exchange is updated weekly. Sirtris is a biopharmaceutical company that's developing drugs to target a class of enzymes called sirtuins.

Lasă un răspuns

Adresa ta de email nu va fi publicată. Câmpurile obligatorii sunt marcate cu *